Avantor (NYSE:AVTR) PT Raised to $28.00 at Stifel Nicolaus

Avantor (NYSE:AVTR) had its target price hoisted by stock analysts at Stifel Nicolaus from $27.00 to $28.00 in a note issued to investors on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ price target points to a potential upside of 1.27% from the stock’s current price.

AVTR has been the subject of a number of other reports. Citigroup downgraded Avantor from a “buy” rating to a “neutral” rating and decreased their price target for the company from $30.00 to $23.00 in a research note on Wednesday, July 10th. Robert W. Baird raised their price target on Avantor from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Monday. Royal Bank of Canada raised their price target on Avantor from $30.00 to $31.00 and gave the company an “outperform” rating in a research note on Monday, July 15th. Barclays decreased their price target on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Friday, June 28th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on Avantor from $23.00 to $25.00 and gave the company a “hold” rating in a research note on Thursday, April 18th. Five research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $27.21.

Avantor Stock Up 5.3 %

Shares of Avantor stock opened at $27.65 on Monday. The business’s 50 day simple moving average is $22.47 and its 200 day simple moving average is $23.71. Avantor has a 52-week low of $16.63 and a 52-week high of $27.66. The firm has a market cap of $18.78 billion, a PE ratio of 70.90, a P/E/G ratio of 2.63 and a beta of 1.32. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.05 and a current ratio of 1.61.

Insider Buying and Selling

In other Avantor news, insider Christophe Couturier 10,000 shares of the firm’s stock in a transaction on Tuesday, July 30th. The was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.50% of the stock is currently owned by insiders.

Institutional Trading of Avantor

Several hedge funds have recently added to or reduced their stakes in the company. Boston Partners lifted its holdings in Avantor by 2.2% during the 1st quarter. Boston Partners now owns 28,561,802 shares of the company’s stock worth $729,298,000 after purchasing an additional 624,369 shares during the last quarter. Artemis Investment Management LLP raised its holdings in Avantor by 14.9% in the 1st quarter. Artemis Investment Management LLP now owns 9,120,083 shares of the company’s stock valued at $233,109,000 after acquiring an additional 1,180,937 shares in the last quarter. Bessemer Group Inc. raised its holdings in Avantor by 4.4% in the 1st quarter. Bessemer Group Inc. now owns 7,099,848 shares of the company’s stock valued at $181,544,000 after acquiring an additional 297,534 shares in the last quarter. Norges Bank acquired a new position in Avantor in the 4th quarter valued at $156,455,000. Finally, Westfield Capital Management Co. LP raised its holdings in Avantor by 27.6% in the 4th quarter. Westfield Capital Management Co. LP now owns 5,418,922 shares of the company’s stock valued at $123,714,000 after acquiring an additional 1,171,976 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.